The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.
 
Alessandra Gennari
Honoraria - Daiichi Sankyo Europe GmbH; Eisai Europe; Gilead Sciences; Lilly; Novartis; Roche
Speakers' Bureau - Eisai Europe
 
Etienne Brain
Honoraria - Lilly; Pfizer; Pfizer; Seagen
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Pfizer; Pfizer; Sandoz-Novartis
Travel, Accommodations, Expenses - Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer
 
Andrea De Censi
Consulting or Advisory Role - Besins Healthcare
 
Oriana Nanni
No Relationships to Disclose
 
Rachel Wuerstlein
No Relationships to Disclose
 
Antonio Frassoldati
Employment - Lilly
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novartis; Seagen
Travel, Accommodations, Expenses - Novartis
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche
 
Valentina Rossi
No Relationships to Disclose
 
Michela Palleschi
No Relationships to Disclose
 
Jean-Louis Alberini
No Relationships to Disclose
 
Federica Matteucci
No Relationships to Disclose
 
Arnoldo Piccardo
No Relationships to Disclose
 
Gian Mauro Sacchetti
No Relationships to Disclose
 
Harun Ilhan
Stock and Other Ownership Interests - Telix Pharmaceuticals (I)
Honoraria - Hermes Medical; Sirtex Medical
Consulting or Advisory Role - Bayer
 
Beatrice Ruffilli
No Relationships to Disclose
 
Simone Nardin
No Relationships to Disclose
 
Manuela Monti
No Relationships to Disclose
 
Matteo Puntoni
Employment - Chiesi (I)
 
Luca Boni
No Relationships to Disclose
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Daiichi-Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen; Viatris; Zuelligpharma
Consulting or Advisory Role - Gilead Sciences; Novartis; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Speakers' Bureau - EPG Communication; Medscape; Springer Healthcare
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Roche/Genentech (Inst)